Nephros (NEPH) 10-Q 8 Aug 18 2018 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 08, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	NEPHROS INC
Entity Central Index Key	1,196,298
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		64,166,988
Trading Symbol	NEPH
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,018

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash	$ 3,484,000	$ 2,194,000
Accounts receivable, net	855,000	836,000
Investment in lease, net-current portion	31,000	20,000
Inventory, net	1,352,000	674,000
Prepaid expenses and other current assets	49,000	85,000
Total current assets	5,771,000	3,809,000
Property and equipment, net	28,000	52,000
Investment in lease, net-less current portion	30,000	39,000
License and supply agreement, net	1,005,000	1,072,000
Other asset	11,000	11,000
Total assets	6,845,000	4,983,000
Current liabilities:
Secured revolving credit facility	153,000	711,000
Current portion of secured note payable	187,000
Accounts payable	679,000	872,000
Accrued expenses	377,000	218,000
Deferred revenue, current portion		70,000
Total current liabilities	1,396,000	1,871,000
Secured note payable, net of current portion	951,000
Unsecured long-term note payable, net of debt issuance costs and debt discount of $0 and $233, respectively		954,000
Long-term portion of deferred revenue		208,000
Total liabilities	2,347,000	3,033,000
Commitments and Contingencies (Note 15)
Stockholders' equity:
Preferred stock, $.001 par value; 5,000,000 shares authorized at June 30, 2018 and December 31, 2017; no shares issued and outstanding at June 30, 2018 and December 31, 2017
Common stock, $.001 par value; 90,000,000 shares authorized at June 30, 2018 and December 31, 2017; 64,166,988 and 55,293,267 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	64,000	55,000
Additional paid-in capital	127,299,000	122,924,000
Accumulated other comprehensive income	74,000	77,000
Accumulated deficit	(122,939,000)	(121,106,000)
Total stockholders' equity	4,498,000	1,950,000
Total liabilities and stockholders' equity	$ 6,845,000	$ 4,983,000

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Debt discount	$ 0	$ 233
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	64,166,988	55,293,267
Common stock, shares outstanding	64,166,988	55,293,267

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net revenues:
Revenues	$ 1,366,000	$ 859,000	$ 2,351,000	$ 1,593,000
Cost of goods sold	536,000	342,000	1,054,000	621,000
Gross margin	830,000	517,000	1,297,000	972,000
Operating expenses:
Research and development	352,000	277,000	641,000	507,000
Depreciation and amortization	40,000	60,000	81,000	119,000
Selling, general and administrative	1,091,000	880,000	2,351,000	1,651,000
Total operating expenses	1,483,000	1,217,000	3,073,000	2,277,000
Loss from operations	(653,000)	(700,000)	(1,776,000)	(1,305,000)
Loss on extinguishment of debt			(199,000)
Interest expense	(28,000)	(64,000)	(114,000)	(130,000)
Interest income	1,000	1,000	2,000	2,000
Other expense	(2,000)	(23,000)	(24,000)	(33,000)
Net loss	(682,000)	(786,000)	(2,111,000)	(1,466,000)
Other comprehensive (loss) income, foreign currency translation adjustments, net of tax	(6,000)	7,000	(3,000)	8,000
Total comprehensive loss	$ (688,000)	$ (779,000)	$ (2,114,000)	$ (1,458,000)
Net loss per common share, basic and diluted	$ (0.01)	$ (0.01)	$ (0.04)	$ (0.03)
Weighted average common shares outstanding, basic and diluted	62,456,668	53,626,707	59,031,649	51,625,048
Product Revenues [Member]
Net revenues:
Revenues	$ 1,216,000	$ 785,000	$ 2,174,000	$ 1,475,000
License, Royalty and Other Revenues [Member]
Net revenues:
Revenues	$ 150,000	$ 74,000	$ 177,000	$ 118,000

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - 6 months ended Jun. 30, 2018 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 55	$ 122,924	$ 77	$ (121,106)	$ 1,950
Balance, shares at Dec. 31, 2017	55,293,267
Net loss				(2,111)	(2,111)
Cumulative effect of adoption of ASC 606				278	278
Net unrealized gains on foreign currency translation, net of tax			(3)		(3)
Issuance of common stock, net of equity issuance costs of $19	$ 9	3,769			3,778
Issuance of common stock, net of equity issuance costs of $19, shares	8,440,669
Cashless exercise of stock options
Cashless exercise of stock options, shares	22,245
Cancelled restricted stock shares
Cancelled restricted stock shares, shares	(45,859)
Exercise of warrants		138			138
Exercise of warrants, shares	456,666
Noncash stock-based compensation		468			468
Balance at Jun. 30, 2018	$ 64	$ 127,299	$ 74	$ (122,939)	$ 4,498
Balance, shares at Jun. 30, 2018	64,166,988

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Changes in Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Statement of Stockholders' Equity [Abstract]
Equity issuance costs	$ 19	$ 152

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating activities:
Net loss	$ (2,111)	$ (1,466)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	14	14
Amortization of license and supply agreement	67	105
Non-cash stock-based compensation, including stock options and restricted stock	468	395
Loss on extinguishment of debt	199
Amortization of debt discount	34	54
Inventory reserve	50
Allowance for doubtful accounts reserve	1	2
Loss on disposal of equipment	10
(Gain) loss on foreign currency transactions	(2)	13
(Increase) decrease in operating assets:
Accounts receivable	(20)	(176)
Inventory	(728)	(124)
Prepaid expenses and other current assets	37	45
Increase (decrease) in operating liabilities:
Accounts payable	(191)	(85)
Accrued expenses	160	100
Deferred revenue		(35)
Net cash used in operating activities	(2,012)	(1,158)
Financing activities:
Proceeds from issuance of common stock, net of equity issuance costs of $19 and $152, respectively	3,778	1,179
Net payments on secured revolving credit facility	(558)
Payments on secured note payable	(49)
Proceeds from exercise of warrants	138
Proceeds from issuance of secured note	1,187
Repayment of unsecured long term note payable	(1,187)
Net cash provided by financing activities	3,309	1,179
Effect of exchange rates on cash	(7)	5
Net increase in cash	1,290	26
Cash, beginning of period	2,194	275
Cash, end of period	3,484	301
Supplemental disclosure of cash flow information
Cash paid for interest	91	77
Cash paid for income taxes	$ 3	$ 4

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Statement of Cash Flows [Abstract]
Equity issuance costs	$ 19	$ 152

Organization and Nature of Oper

Organization and Nature of Operations	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	Note 1 – Organization and Nature of Operations Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. The Company was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced end stage renal disease (“ESRD”) therapy technology and products. Today, the Company has two U.S. Food and Drug Administration-cleared products in the hemodiafiltration (“HDF”) market that deliver therapy to ESRD patients. These are the OLpūr mid-dilution HDF filter or “dialyzer,” designed expressly for HDF therapy, and the OLpūr H2H HDF module, an add-on module designed to allow the most common types of hemodialysis machines to be used for HDF therapy. Beginning in 2009, Nephros introduced an additional, complementary business developing and marketing high performance liquid purification filters to meet the demand for water purification in certain medical markets. The Company’s filters, generally classified as ultrafilters, are primarily used in hospitals for the prevention of infection from water-borne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. The Company is also exploring water purification applications in several commercial markets, including food and beverage, data center cooling, and military field applications. The U.S. facilities, located at 380 Lackawanna Place, South Orange, New Jersey, 07079, are used to house the Company’s corporate headquarters and research facilities. On June 4, 2003, Nephros International Limited was incorporated under the laws of Ireland as a wholly-owned subsidiary of the Company. In August 2003, the Company established a European office in Dublin, Ireland.

Basis of Presentation and Liqui

Basis of Presentation and Liquidity	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Liquidity	Note 2 – Basis of Presentation and Liquidity Interim Financial Information The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for annual financial statements. Results as of and for the three and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. The condensed consolidated interim financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates. Included in these estimates are assumptions about the collection of accounts receivable, value of inventories, useful life of fixed assets and intangible assets, and assumptions used in determining stock compensation such as expected volatility and risk-free interest rate. Liquidity The Company has sustained operating losses and expects such losses to continue over the next several quarters. Net losses from operations since inception have generated an accumulated deficit of approximately $122,939,000 as of June 30, 2018. On April 10, 2018, the Company completed a private placement transaction whereby the Company sold 6,540,669 shares of its common stock for aggregate net proceeds of approximately $2,943,000. The Company believes that its cash will be sufficient to fund the Company’s current operating plan through at least the next twelve months from the date of issuance of the accompanying condensed consolidated financial statements.

Major Customers and Concentrati

Major Customers and Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2018
Risks and Uncertainties [Abstract]
Major Customers and Concentration of Credit Risk	Note 3 – Major Customers and Concentration of Credit Risk For the three and six months ended June 30, 2018, four customers accounted for 42% of the Company’s revenues. For the three months ended June 30, 2017, four customers accounted for 54% of the Company’s revenues. For the six months ended June 30, 2017, four customers accounted for 56% of the Company’s revenues. As of June 30, 2018, three customers accounted for 39% of the Company’s accounts receivable. As of December 31, 2017, two customers accounted for 29% of the Company’s accounts receivable. For the three months ended June 30, 2018 and 2017, the following customers accounted for the following percentages of the Company’s revenues, respectively: Customer 2018 2017 A 13 % 16 % B 13 % 14 % C 11 % 12 % D 5 % 12 % For the six months ended June 30, 2018 and 2017, the following customers accounted for the following percentages of the Company’s revenues, respectively: Customer 2018 2017 A 14 % 21 % B 13 % 13 % C 9 % 11 % D 6 % 11 % As of June 30, 2018 and December 31, 2017, the following customers accounted for the following percentages of the Company’s accounts receivable, respectively: Customer June 30, 2018 December 31, 2017 B 15 % 18 % E 12 % - % F 12 % - % G - % 11 % The Company provides credit terms to customers in connection with purchases of the Company’s products. Management periodically reviews customer account activity in order to assess the adequacy of the allowances provided for potential collection issues and returns. Factors considered include economic conditions, and each customer’s payment and return history and creditworthiness. Adjustments, if any, are made to reserve balances following the completion of these reviews to reflect management’s best estimate of potential losses. The allowance for doubtful accounts was approximately $2,000 and $1,000 as of June 30, 2018 and December 31, 2017, respectively. There was no allowance for sales returns at June 30, 2018 or December 31, 2017.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2018
Revenue Recognition [Abstract]
Revenue Recognition	Note 4 – Revenue Recognition The Company adopted Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, as of January 1, 2018 using the modified retrospective method. ASC 606 prescribes a five step model for recognizing revenue, which includes (i) identifying contracts with customers; (ii) identifying performance obligations; (iii) determining the transaction price; (iv) allocating the transaction price and (v) recognizing revenue. The Company recognizes revenue related to product sales when product is shipped via external logistics provider and the other criteria of ASC 606 are met. Product revenue is recorded net of returns and allowances. In addition to product revenue, the Company recognizes revenue related to license, royalty and other agreements in accordance with the five step model in ASC 606. In accordance with the adoption of ASC 606, the remaining deferred revenue of approximately $278,000 related to license revenue as of December 31, 2017 was recognized as a cumulative effect adjustment to accumulated deficit as of January 1, 2018. License, royalty and other revenue recognized for the three and six months ended June 30, 2018 and 2017 is comprised of: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Royalty revenue under the Sublicense Agreement with CamelBak (1) $ 100,000 $ 25,000 $ 100,000 $ 25,000 Royalty revenue under the License Agreement with Bellco 31,000 31,000 58,000 58,000 License revenue under the License Agreement with Bellco (2) - 18,000 - 35,000 Other revenue 19,000 - 19,000 - Total license, royalty and other revenue $ 150,000 $ 74,000 $ 177,000 $ 118,000 (1) In May 2015, the Company entered into a Sublicense Agreement with CamelBak Products, LLC (“CamelBak”). Under the Sublicense Agreement, the Company granted CamelBak an exclusive, non-transferable, worldwide (with the exception of Italy) sublicense and license, in each case solely to market, sell, distribute, import and export the Company’s individual water treatment device. In exchange for the rights granted to CamelBak, CamelBak agreed, through December 31, 2022, to pay the Company a percentage of the gross profit on any sales made to a branch of the U.S. military, subject to certain exceptions, and to pay a fixed per-unit fee for any other sales made. CamelBak is also required to meet or exceed certain minimum annual fees payable to the Company, and if such fees are not met or exceeded, the Company may convert the exclusive sublicense to a non-exclusive sublicense with respect to non-U.S. military sales. (2) In June 2011, the Company entered into a License Agreement with Bellco S.r.l. (“Bellco”). Under the License Agreement, as amended, the Company granted Bellco a license to manufacture, market and sell the Company’s patented mid-dilution dialysis filters (the “Products”) under its own name, label and CE mark in certain countries on an exclusive basis, and to do the same on a non-exclusive basis in certain other countries (see Note 15 – Commitments and Contingencies). The following tables present the Company’s revenue for the three and six months ended June 30, 2018 under the ASC 606 model as compared to revenue under the previous accounting guidance: Three Months Ended June 30, 2018 Revenue as reported Revenue under previous accounting guidance Difference Product revenue $ 1,216,000 $ 1,216,000 $ - Royalty revenue under the Sublicense Agreement with CamelBak 100,000 100,000 - Royalty revenue under the License Agreement with Bellco 31,000 31,000 - License revenue under the License Agreement with Bellco (1) - 18,000 (18,000 ) Other revenue 19,000 19,000 - Total net revenues $ 1,366,000 $ 1,384,000 $ (18,000 ) Six Months Ended June 30, 2018 Revenue as reported Revenue under previous accounting guidance Difference Product revenue $ 2,174,000 $ 2,174,000 $ - Royalty revenue under the Sublicense Agreement with CamelBak 100,000 100,000 - Royalty revenue under the License Agreement with Bellco 58,000 58,000 - License revenue under the License Agreement with Bellco (1) - 35,000 (35,000 ) Other revenue 19,000 19,000 - Total net revenues $ 2,351,000 $ 2,386,000 $ (35,000 ) (1) Under ASC 606, amounts received related to the license under the License Agreement with Bellco would have been recognized as revenue at the time that the license was transferred, which was at the time the payments were received by the Company. Under previous accounting guidance, amounts received under the License Agreement with Bellco were deferred and recognized as revenue over the term of the License Agreement.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 5 – Fair Value of Financial Instruments The carrying amounts of cash, accounts receivable, secured revolving credit facility, accounts payable and accrued expenses approximate fair value due to the short-term maturity of these instruments. The carrying amounts of the investment in lease, net, the secured long-term note payable and the unsecured long-term note payable approximate fair value as of June 30, 2018 and December 31, 2017 because those financial instruments bear interest at rates that approximate current market rates for similar agreements with similar maturities and credit.

Stock Plans and Share-Based Pay

Stock Plans and Share-Based Payments	6 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Plans and Share-Based Payments	Note 6 – Stock Plans and Share-Based Payments Stock Options The fair value of stock options is recognized as stock-based compensation expense in the Company’s condensed consolidated statement of operations and comprehensive loss. The Company calculates employee stock-based compensation expense in accordance with ASC 718. The Company accounts for stock options granted to consultants under the provisions of ASC 505-50, and as such, these stock options are revalued at each reporting period through the vesting period. The fair value of the Company’s stock options is estimated using a Black-Scholes option valuation model. This model requires the input of highly subjective assumptions and elections including expected stock price volatility and the estimated life of each award. The fair value of stock-based awards is amortized over the vesting period of the award. Stock-Based Compensation Stock-based compensation expense related to stock options was approximately $124,000 and $111,000 for the three months ended June 30, 2018 and 2017, respectively. For the three months ended June 30, 2018, approximately $118,000 and approximately $6,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying condensed consolidated statement of operations and comprehensive loss. For the three months ended June 30, 2017, approximately $103,000 and approximately $8,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying condensed consolidated statement of operations and comprehensive loss. Stock-based compensation expense related to stock options was approximately $253,000 and $213,000 for the six months ended June 30, 2018 and 2017, respectively. For the six months ended June 30, 2018, approximately $237,000 and $16,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying condensed consolidated statement of operations and comprehensive loss. For the six months ended June 30, 2017, approximately $194,000 and $19,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying condensed consolidated statement of operations and comprehensive loss. During the three months ended March 31, 2018, previously issued stock options were modified for an employee who is no longer employed with the Company. As a result of this modification, included in the approximately $16,000 of research and development expenses is approximately $12,000 of stock option modification expense on the accompanying condensed consolidated statement of operations and comprehensive loss for the six months ended June 30, 2018. There was no tax benefit related to expense recognized in the three months ended June 30, 2018 and 2017, as the Company is in a net operating loss position. As of June 30, 2018, there was approximately $1,132,000 of total unrecognized compensation expense related to unvested stock-based awards granted under the equity compensation plans. Approximately $230,000 of the $1,132,000 total unrecognized compensation expense will be recognized at the time that certain performance conditions are met. The remaining unrecognized compensation expense of approximately $902,000 will be amortized over the weighted average remaining requisite service period of 2.1 years. Such amount does not include the effect of future grants of equity compensation, if any. Restricted Stock Total stock-based compensation expense for restricted stock was approximately $103,000 and $85,000 for the three months ended June 30, 2018 and 2017. Approximately $90,000 and $85,000 is included in selling, general and administrative expenses on the accompanying condensed consolidated statement of operations and comprehensive loss for the three months ended June 30, 2018 and 2017, respectively. Approximately $13,000 is included in research and development expenses on the accompanying condensed consolidated statement of operations and comprehensive loss for the three months ended June 30, 2018. Total stock-based compensation expense for restricted stock was approximately $215,000 and $182,000 for the six months ended June 30, 2018 and 2017. Approximately $190,000 and $182,000 is included in selling, general and administrative expenses on the accompanying condensed consolidated statement of operations and comprehensive loss for the six months ended June 30, 2018 and 2017, respectively. Approximately $25,000 is included in research and development expenses on the accompanying condensed consolidated statement of operations and comprehensive loss for the six months ended June 30, 2018. As of June 30, 2018, there was no unrecognized compensation expense related to restricted stock.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Warrants	Note 7 – Warrants During the three months ended June 30, 2018, warrants to purchase 456,666 shares of the Company’s common stock were exercised, resulting in proceeds of approximately $138,000 and the issuance of 456,666 shares of the Company’s common stock. Of the warrants exercised during the three months ended June 30, 2018, warrants to purchase 73,333 shares of the Company’s common stock were exercised by members of management, resulting in proceeds of approximately $22,000. There were no warrants exercised during the six months ended June 30, 2017.

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Net Loss Per Common Share	Note 8 – Net Loss per Common Share Basic loss per common share is calculated by dividing net loss available to common shareholders by the number of weighted average common shares issued and outstanding. Diluted loss per common share is calculated by dividing net loss available to common shareholders by the weighted average number of common shares issued and outstanding for the period, plus amounts representing the dilutive effect from the exercise of stock options and warrants, as applicable. The Company calculates dilutive potential common shares using the treasury stock method, which assumes the Company will use the proceeds from the exercise of stock options and warrants to repurchase shares of common stock to hold in its treasury stock reserves. The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive: June 30, 2018 2017 Shares underlying warrants outstanding 6,642,344 7,432,342 Shares underlying options outstanding 6,644,527 5,459,015 Unvested restricted stock - 17,756

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Pronouncements	Note 9 – Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers,” related to revenue recognition. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to be entitled to in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in prior accounting guidance. ASU 2014-09 provides alternative methods of initial adoption and was to be effective for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. Early adoption was not permitted. In August 2015, the FASB issued ASU No. 2015-14, “Revenue from Contracts with Customers: Deferral of the Effective Date.” This ASU deferred the effective date of ASU No. 2014-09 for all entities for one year. In March, April and May 2016, the FASB issued ASU No. 2016-08, ASU No. 2016-10 and ASU No. 2016-12, respectively, which clarified implementation guidance, including the guidance on principal versus agent considerations, performance obligations and licensing and assessments of collectability and noncash considerations. Public business entities, certain not-for-profit entities, and certain employee benefit plans are required to apply the guidance in ASU 2014-09 to fiscal years beginning after December 15, 2017, including interim reporting periods within that fiscal year. The Company adopted the new revenue recognition standard as of January 1, 2018 using the modified retrospective method, which requires the cumulative effect of adoption, if any, to be recognized as an adjustment to opening accumulated deficit in the period of adoption. The majority of the Company’s revenue relates to the sale of finished products to various customers, and the adoption did not have any impact on revenue recognized from these transactions. The Company completed its analysis of the impact on certain less significant transactions involving third-party arrangements, and as a result of the analysis, the Company accelerated the remaining approximately $278,000 of deferred revenue to be recognized under the License Agreement with Bellco as of December 31, 2017 and recorded a cumulative effect adjustment to opening accumulated deficit as of January 1, 2018. In January 2016, the FASB issued ASU No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities,” that modifies certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The accounting standard update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and early adoption was permitted. The Company adopted this guidance as of January 1, 2018 and the guidance did not have an impact on its consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments,” which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows in order to reduce diversity in practice. The guidance was effective for the Company beginning in the first quarter of fiscal year 2018. Early adoption was permitted. The Company adopted the guidance as of January 1, 2018 and the guidance did not have a significant impact on its consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, “Restricted Cash,” which clarifies how restricted cash is presented and classified in the statement of cash flows. The guidance was effective for the Company beginning in the first quarter of fiscal year 2018. Early adoption was permitted. The Company adopted the guidance as of January 1, 2018 and the guidance did not have an impact on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, “Clarifying the Definition of a Business,” which clarifies the definition of a business in a business combination. The guidance was effective for the Company beginning in the first quarter of fiscal year 2018. Early adoption was permitted. The Company adopted the guidance as of January 1, 2018 and the guidance did not have an impact on its consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation,” which requires modification accounting to be used on share-based payment awards if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. The guidance was effective for the Company beginning in the first quarter of fiscal year 2018. The Company adopted the guidance as of January 1, 2018 and the guidance did not have an impact on its consolidated financial statements. Recent Accounting Pronouncements, Not Yet Effective In February 2016, the FASB issued ASU No. 2016-02, “Leases,” which discusses how an entity should account for lease assets and lease liabilities. The guidance specifies that an entity who is a lessee under lease agreements should recognize lease assets and lease liabilities for those leases classified as operating leases under previous FASB guidance. Accounting for leases by lessors is largely unchanged under the new guidance. The guidance is effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The Company is assessing the impact of adopting this guidance on its consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted beginning in the first quarter of fiscal year 2019. The Company is assessing the impact of adopting this guidance on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment,” which simplifies the test for goodwill impairment. The guidance is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted for interim or annual goodwill impairments tests after January 1, 2017. The Company is assessing the impact of adopting this guidance on its consolidated financial statements. In May 2018, the FASB issued ASU 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting,” which expands the scope of ASC 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance is effective for the Company beginning in the first quarter of fiscal year 2019. Early adoption is permitted. The Company is assessing the impact of adopting this guidance on its consolidated financial statements.

Inventory, Net

Inventory, Net	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Inventory, Net	Note 10 – Inventory, net Inventory is stated at the lower of cost or net realizable value using the first-in, first-out method and consists of raw materials and finished goods. The Company’s inventory as of June 30, 2018 and December 31, 2017 was as follows: June 30, 2018 December 31, 2017 (Unaudited) (Audited) Finished goods $ 1,345,000 $ 654,000 Raw materials 74,000 51,000 Less: inventory reserve (67,000 ) (31,000 ) Total inventory, net $ 1,352,000 $ 674,000

Secured Note Payable

Secured Note Payable	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Secured Note Payable	Note 11 – Secured Note Payable On March 27, 2018, the Company entered into a Secured Promissory Note Agreement (the “Secured Note”) with Tech Capital, LLC (“Tech Capital”) for a principal amount of $1,187,000. As of June 30, 2018, the principal balance of the Secured Note was approximately $1,138,000. The Company used the proceeds from the Secured Note to repay the Company’s 11% unsecured promissory notes issued in June 2016 pursuant to the Note and Warrant Agreement (see Note 13 – Unsecured Promissory Notes and Warrants). The Secured Note has a maturity date of April 1, 2023. The unpaid principal balance accrues interest at a rate of 8% per annum. Principal and interest payments are due on the first day of each month commencing on May 1, 2018. The Secured Note is subject to the terms and conditions of and is secured by security interests granted by the Company in favor of Tech Capital under the Loan and Security Agreement between the Company and Tech Capital, dated August 16, 2017 and all of the riders and amendments thereto (the “Loan Agreement”) (see Note 12 – Secured Revolving Credit Facility). An event of default under such Loan Agreement shall be an event of default under the Secured Note, and vice versa. In the event the principal balance under the Loan Agreement is due, all amounts due under the Secured Note shall also be due. During the three months ended June 30, 2018, the Company made payments under the Secured Note of approximately $72,000. Approximately $23,000 of the $72,000 was recognized as interest expense on the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2018. Debt issuance costs of approximately $6,000 were recognized as interest expense on the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2018. As of June 30, 2018, future principal maturities are as follows: 2018 $ 101,000 2019 214,000 2020 231,000 2021 250,000 2022 271,000 2023 71,000 Total $ 1,138,000

Secured Revolving Credit Facili

Secured Revolving Credit Facility	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Secured Revolving Credit Facility	Note 12 – Secured Revolving Credit Facility On August 17, 2017, the Company entered into the Loan Agreement with Tech Capital. The Loan Agreement provides for a secured asset-based revolving credit facility of up to $1,000,000, which the Company may draw upon and repay from time to time during the term of the Loan Agreement. The outstanding principal balance of the Loan Agreement was approximately $153,000 and $711,000 as of June 30, 2018 and December 31, 2017, respectively. The Company is using these proceeds for working capital and general corporate purposes. The Loan Agreement has a term of 12 months, which will automatically renew for successive 12-month periods unless cancelled. Availability under the Loan Agreement will be based upon periodic borrowing base certifications valuing certain of the Company’s accounts receivable and inventory. Outstanding borrowings under the Loan Agreement accrue interest, which shall be payable monthly based on the average daily outstanding balance, at a rate equal to 3.5% plus the prime rate per annum, provided that such prime rate shall not be less than 4.25% per annum. As of June 30, 2018, the current interest rate was 8.50% per annum. The Company also granted to Tech Capital a first priority security interest in its assets, including its accounts receivable and inventory, to secure all of its obligations under the Loan Agreement. In addition, Nephros International Limited, the Company’s wholly-owned subsidiary, unconditionally guaranteed the Company’s obligations under the Loan Agreement. In connection with the Loan Agreement, the Company incurred fees of approximately $12,000 related to the issuance of the revolving credit facility. These debt issuance costs were recognized as interest expense during the three months ended September 30, 2017. For the three and six months ended June 30, 2018, approximately $3,000 and $9,000, respectively, was recognized as interest expense on the condensed consolidated statement of operations and comprehensive loss. As of June 30, 2018, approximately $1,000 of the $9,000 of interest expense incurred for the six months ended June 30, 2018 is included in accrued expenses on the condensed consolidated balance sheet.

Unsecured Promissory Notes and

Unsecured Promissory Notes and Warrants	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Unsecured Promissory Notes and Warrants	Note 13 – Unsecured Promissory Notes and Warrants In June 2016, the Company entered into a Note and Warrant Agreement (the “Note and Warrant Agreement”) with new creditors as well as existing stockholders under which the Company issued unsecured promissory notes and warrants resulting in total gross proceeds to the Company during June 2016 of approximately $1,187,000. As of December 31, 2017, the portion of the outstanding notes held by related parties comprised of persons controlled by a member of management and by Lambda Investors LLC (“Lambda”), the majority shareholder, amounted to $30,000 and $300,000, respectively. The outstanding principal under the notes accrued interest at a rate of 11% per annum. The notes required the Company to make interest only payments on a semi-annual basis, with all outstanding principal under the notes being repayable in cash on the third anniversary of the date of issuance. In addition to the notes, the Company issued warrants to purchase approximately 2.4 million shares of the Company’s common stock. The portion of the gross proceeds allocated to the warrants of approximately $393,000 was accounted for as additional paid-in capital resulting in a debt discount. The debt discount, which included approximately $9,000 of debt issuance costs in addition to the fair value of the warrants, was being amortized to interest expense using the effective interest method in accordance with ASC 835 over the term of the Note and Warrant Agreement. On March 30, 2018, using proceeds from the Secured Note, the principal balance of the notes, along with the remaining accrued interest of approximately $43,000, was repaid in full. While the notes were outstanding, approximately $195,000 of interest was paid to noteholders. The remaining debt discount of approximately $199,000 was written off and recorded as loss on extinguishment of debt in the Company’s condensed consolidated statements of operations and comprehensive loss. For the six months ended June 30, 2018, approximately $34,000 was recognized as amortization of debt discount and is included in interest expense on the condensed consolidated statement of operations and comprehensive loss. For the three and six months ended June 30, 2017, approximately $27,000 and $54,000, respectively, was recognized as amortization of debt discount and is included in interest expense on the condensed consolidated statement of operations and comprehensive loss. For the six months ended June 30, 2018, approximately $30,000 of interest expense was incurred. For the three and six months ended June 30, 2017, approximately $33,000 and $66,000, respectively, of interest expense was incurred. For the six months ended June 30, 2018, the amount of interest expense recognized related to related parties comprised of entities controlled by a member of management and by Lambda was approximately $1,000 and $8,000, respectively. For the six months ended June 30, 2017, the amount of interest expense recognized related to related parties comprised of entities controlled by a member of management and by Lambda was approximately $2,000 and $16,000, respectively. For the three months ended June 30, 2017, the amount of interest expense recognized related to related parties comprised of entities controlled by a member of management and by Lambda was approximately $1,000 and $8,000, respectively.

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Stockholders’ Equity	Note 14 – Stockholders’ Equity April 2018 Private Placement On April 10, 2018, the Company entered into a Stock Purchase Agreement with certain accredited investors identified therein pursuant to which the Company issued and sold in a private placement 6,540,669 shares of the Company’s common stock resulting in gross proceeds to the Company of approximately $2,943,000. The purchase price for each share was $0.45. Proceeds, net of equity issuance costs of $19,000, recorded as a result of the private placement were approximately $2,924,000. Of the 6,540,669 shares of the Company’s common stock issued, 219,000 shares, resulting in proceeds of $98,550, were sold to members of management, including immediate family members. March 2017 Private Placement On March 17, 2017, the Company entered into a Securities Purchase Agreement with certain accredited investors identified therein pursuant to which the Company issued and sold in a private placement 4,059,994 units of its securities resulting in gross proceeds to the Company of approximately $1,218,000. Each unit consisted of one share of the Company’s common stock and a five-year warrant to purchase one additional share of the Company’s common stock. The purchase price for each unit was $0.30. The warrants are exercisable at a price of $0.30 per share and are indexed to the Company’s common stock; therefore, the Company is accounting for the warrants as a component of equity. The portion of the gross proceeds received from certain members of management and existing stockholders amounted to $315,000. Proceeds, net of equity issuance costs of $152,000, recorded as a result of the private placement were approximately $1,066,000. In addition to the equity issuance costs incurred as a result of the private placement, the Company also issued a warrant to purchase 81,199 shares of its common stock to the placement agent engaged in connection with the private placement. The form and terms of the placement agent warrant is substantially the same as the form of warrants issued to the investors under the Securities Purchase Agreement, except that the exercise price is $0.33 per share. July 2015 Purchase Agreement and Registration Rights Agreement On July 24, 2015, the Company entered into both a securities purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Under the terms and subject to the conditions of the securities purchase agreement, the Company has the right to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $10.0 million in shares of the Company’s common stock, subject to certain limitations, from time to time, over the 36-month period commencing on September 4, 2015. Pursuant to the securities purchase agreement, during the six months ended June 30, 2018 and 2017, the Company issued and sold 1,900,000 and 300,000 shares of its common stock, respectively, to Lincoln Park. The issuance of the common shares to Lincoln Park resulted in gross proceeds of $854,000 and $113,000 for the six months ended June 30, 2018 and 2017, respectively. The Company did not issue or sell any stock to Lincoln Park during the three months ended June 30, 2018.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15 – Commitments and Contingencies Manufacturing and Suppliers The Company has not, and does not intend in the near future, to manufacture any of its products and components. With regard to the OLpūr MD190 and MD220, on June 27, 2011, the Company entered into a License Agreement (the “License Agreement”), effective July 1, 2011, with Bellco S.r.l. (“Bellco”), an Italy-based supplier of hemodialysis and intensive care products, for the manufacturing, marketing and sale of our patented mid-dilution dialysis filters (the “Products”). Under the License Agreement, the Company granted Bellco a license to manufacture, market and sell the Products under its own name, label and CE mark in Italy, France, Belgium, Spain and Canada on an exclusive basis, and to do the same on a non-exclusive basis in the United Kingdom and Greece and, upon our written approval, other European countries where the Company does not sell the Products as well as non-European countries (referred to as the “Territory”). On February 19, 2014, the Company entered into the first amendment to the License Agreement with Bellco, pursuant to which the Company and Bellco agreed to extend the term of the License Agreement from December 31, 2016 to December 31, 2021. The first amendment also expands the Territory covered by the License Agreement to include, on an exclusive basis, Sweden, Denmark, Norway and Finland and on a non-exclusive basis, Korea, Mexico, Brazil, China and the Netherlands. The first amendment further provides new minimum sales targets which, if not satisfied, will, at the discretion of the Company, result in conversion of the license to non-exclusive status. The Company has agreed to reduce the fixed royalty payment payable to the Company for the period beginning on January 1, 2015 through and including December 31, 2021. Beginning on January 1, 2015 through and including December 31, 2021, Bellco will pay the Company a royalty based on the number of units of Products sold per year in the Territory as follows: for the first 125,000 units sold in total, €1.75 (approximately $2.10) per unit; thereafter, €1.25 (approximately $1.50) per unit. In addition, the first amendment provides that, in the event that the Company pursues a transaction to sell, assign or transfer all right, title and interest to the licensed patents to a third party, the Company will provide Bellco with written notice thereof and a right of first offer with respect to the contemplated transaction for a period of 30 days. In accordance with the adoption of ASC 606, the remaining deferred revenue of approximately $278,000 related to license revenue as of December 31, 2017 was recognized as a cumulative effect adjustment to accumulated deficit as of January 1, 2018. During the three and six months ended June 30, 2017, approximately $18,000 and $35,000, respectively, was recognized as license revenue. The Company recognized royalty income from Bellco pursuant to the License Agreement of approximately $31,000 for each of the three months ended June 30, 2018 and 2017. The Company recognized royalty income from Bellco pursuant to the License Agreement of approximately $58,000 for each of the six months ended June 30, 2018 and 2017. License and Supply Agreement On April 23, 2012, the Company entered into a License and Supply Agreement (the “License and Supply Agreement”) with Medica S.p.A. (“Medica”), an Italy-based medical product manufacturing company, for the marketing and sale of certain filtration products based upon Medica’s proprietary Medisulfone ultrafiltration technology in conjunction with the Company’s filtration products, and for an exclusive supply arrangement for the filtration products. Under the License and Supply Agreement, Medica granted to the Company an exclusive license, with right of sublicense, to market, promote, distribute, offer for sale and sell the filtration products worldwide, excluding Italy for the first three years, during the term of the License and Supply Agreement. In addition, the Company granted to Medica an exclusive license under the Company’s intellectual property to make the filtration products during the term of the License and Supply Agreement. On May 5, 2017, the Company and Medica entered into a Third Amendment to the License and Supply Agreement (the “Third Amendment”), which expanded the products covered by the original License and Supply Agreement to include both certain filtration products based on Medica’s proprietary Versatile microfiber technology and certain filtration products based on Medica’s proprietary Medisulfone ultrafiltration technology. The Third Amendment also limits the territory in which Medica granted the Company an exclusive license, with right of sublicense, to market, promote, distribute, offer for sale, and sell the filtration products. On September 26, 2017, the Company and Medica entered into a Fourth Amendment to the License and Supply Agreement (the “Fourth Amendment”), which extended the term of the License and Supply Agreement from December 31, 2022 to December 31, 2025, unless earlier terminated by either party in accordance with the terms of the License and Supply Agreement. In exchange for the rights granted, the Company agreed to make certain minimum annual aggregate purchases from Medica over the term of the License and Supply Agreement. For the year ended December 31, 2018, the Company has agreed to make minimum annual aggregate purchases from Medica of €2,500,000 (approximately $3,000,000). As of June 30, 2018, the Company’s aggregate purchase commitments totaled approximately €949,000 (approximately $1,139,000). In exchange for the license, the gross value of the intangible asset capitalized was approximately $2,250,000. License and supply agreement, net, on the condensed consolidated balance sheet is approximately $1,005,000 and $1,072,000 as of June 30, 2018 and December 31, 2017, respectively. Accumulated amortization is approximately $1,245,000 and $1,178,000 as of June 30, 2018 and December 31, 2017, respectively. The intangible asset is being amortized as an expense over the life of the License and Supply Agreement. Approximately $33,000 and $53,000 has been charged to amortization expense for the three months ended June 30, 2018 and 2017, respectively, on the condensed consolidated statement of operations and comprehensive loss. Approximately $67,000 and $105,000 has been charged to amortization expense for the six months ended June 30, 2018 and 2017, respectively, on the condensed consolidated statement of operations and comprehensive loss. As of September 2013, the Company has an understanding with Medica whereby the Company has agreed to pay interest to Medica at a 12% annual rate calculated on the principal amount of any outstanding invoices that are not paid pursuant to the original payment terms. For the three and six months ended June 30, 2018, approximately $2,000 and $12,000 of interest, respectively, was recognized as interest expense. For the three and six months ended June 30, 2017, approximately $2,000 and $10,000 of interest, respectively, was recognized as interest expense. In addition, for the period beginning April 23, 2014 through December 31, 2025, the Company will pay Medica a royalty rate of 3% of net sales of the filtration products sold, subject to reduction as a result of a supply interruption pursuant to the terms of the License and Supply Agreement. Approximately $36,000 and $22,000 for the three months ended June 30, 2018 and 2017, respectively, was recognized as royalty expense and is included in cost of goods sold on the condensed consolidated statement of operations and comprehensive loss. Approximately $65,000 and $41,000 for the six months ended June 30, 2018 and 2017, respectively, was recognized as royalty expense and is included in cost of goods sold on the condensed consolidated statement of operations and comprehensive loss. Approximately $36,000 and $34,000 in royalties are included in accounts payable as of June 30, 2018 and December 31, 2017, respectively. Contractual Obligations The Company entered into an operating lease that began in December 2017 for 380 Lackawanna Place, South Orange, New Jersey 07079, which consists of approximately 7,700 square feet of space. The rental agreement expires in November 2022 with a monthly cost of approximately $11,000. Approximately $11,000 related to a security deposit for this U.S. office facility is classified as other assets on the condensed consolidated balance sheet as of June 30, 2018 and December 31, 2017. The Company uses these facilities to house its corporate headquarters and research facilities. The lease agreement for the office space in Ireland was entered into on August 1, 2017 and includes a twelve month term. Rent expense for the three months ended June 30, 2018 and 2017 totaled $37,000 and $28,000, respectively. Rent expense for the six months ended June 30, 2018 and 2017 totaled $88,000 and $59,000, respectively. As of June 30, 2018, minimum lease payments are as follows: 2018 $ 66,000 2019 136,000 2020 140,000 2021 145,000 2022 136,000 Investment in Lease, net On October 8, 2015, the Company entered into an equipment lease agreement with Biocon 1, LLC. The lease commenced on January 1, 2016 with a term of 60 months and monthly rental payments of approximately $1,800 will be paid to the Company. At the completion of the lease term, Biocon 1, LLC will own the equipment provided under the agreement. An investment in lease was established for the direct financing lease receivable at the present value of the future minimum lease payments. Interest income will be recognized monthly over the lease term using the effective-interest method. Cash received will be applied against the direct financing lease receivable and will be presented within changes in operating assets and liabilities in the operating section of the Company’s condensed consolidated statement of cash flows. At lease inception, an investment in lease of approximately $92,000 was recorded, net of unearned interest of approximately $14,000. Approximately $1,000 was recognized in interest income during each of the three months ended June 30, 2018 and 2017. Approximately $2,000 was recognized in interest income during each of the six months ended June 30, 2018 and 2017. As of June 30, 2018, investment in lease, net-current portion is approximately $31,000, net of unearned interest of $2,000. As of June 30, 2018, investment in lease, net-noncurrent portion is approximately $30,000, net of unearned interest of $2,000. As of June 30, 2018, scheduled maturities of minimum lease payments receivable were as follows: 2018 20,000 2019 19,000 2020 22,000 61,000 Less: Current portion (31,000 ) Investment in lease, net – less current portion $ 30,000 Included in the above scheduled maturities of minimum lease payments receivable, approximately $12,000 was due as of June 30, 2018.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Event	Note 16 – Subsequent Event On July 2, 2018, the Company formed a new, wholly-owned subsidiary, Specialty Renal Products, Inc. (“SRP”), to drive the development of its 2 nd

Basis of Presentation and Liq25

Basis of Presentation and Liquidity (Policies)	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Interim Financial Information	Interim Financial Information The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for annual financial statements. Results as of and for the three and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. The condensed consolidated interim financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates. Included in these estimates are assumptions about the collection of accounts receivable, value of inventories, useful life of fixed assets and intangible assets, and assumptions used in determining stock compensation such as expected volatility and risk-free interest rate.
Liquidity	Liquidity The Company has sustained operating losses and expects such losses to continue over the next several quarters. Net losses from operations since inception have generated an accumulated deficit of approximately $122,939,000 as of June 30, 2018. On April 10, 2018, the Company completed a private placement transaction whereby the Company sold 6,540,669 shares of its common stock for aggregate net proceeds of approximately $2,943,000. The Company believes that its cash will be sufficient to fund the Company’s current operating plan through at least the next twelve months from the date of issuance of the accompanying condensed consolidated financial statements.

Major Customers and Concentra26

Major Customers and Concentration of Credit Risk (Tables)	6 Months Ended
	Jun. 30, 2018
Risks and Uncertainties [Abstract]
Schedule of Revenues and Receivable Major Customers	For the three months ended June 30, 2018 and 2017, the following customers accounted for the following percentages of the Company’s revenues, respectively: Customer 2018 2017 A 13 % 16 % B 13 % 14 % C 11 % 12 % D 5 % 12 % For the six months ended June 30, 2018 and 2017, the following customers accounted for the following percentages of the Company’s revenues, respectively: Customer 2018 2017 A 14 % 21 % B 13 % 13 % C 9 % 11 % D 6 % 11 % As of June 30, 2018 and December 31, 2017, the following customers accounted for the following percentages of the Company’s accounts receivable, respectively: Customer June 30, 2018 December 31, 2017 B 15 % 18 % E 12 % - % F 12 % - % G - % 11 %

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2018
Revenue Recognition [Abstract]
Schedule of License, Royal and Other Revenue	License, royalty and other revenue recognized for the three and six months ended June 30, 2018 and 2017 is comprised of: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Royalty revenue under the Sublicense Agreement with CamelBak (1) $ 100,000 $ 25,000 $ 100,000 $ 25,000 Royalty revenue under the License Agreement with Bellco 31,000 31,000 58,000 58,000 License revenue under the License Agreement with Bellco (2) - 18,000 - 35,000 Other revenue 19,000 - 19,000 - Total license, royalty and other revenue $ 150,000 $ 74,000 $ 177,000 $ 118,000 (1) In May 2015, the Company entered into a Sublicense Agreement with CamelBak Products, LLC (“CamelBak”). Under the Sublicense Agreement, the Company granted CamelBak an exclusive, non-transferable, worldwide (with the exception of Italy) sublicense and license, in each case solely to market, sell, distribute, import and export the Company’s individual water treatment device. In exchange for the rights granted to CamelBak, CamelBak agreed, through December 31, 2022, to pay the Company a percentage of the gross profit on any sales made to a branch of the U.S. military, subject to certain exceptions, and to pay a fixed per-unit fee for any other sales made. CamelBak is also required to meet or exceed certain minimum annual fees payable to the Company, and if such fees are not met or exceeded, the Company may convert the exclusive sublicense to a non-exclusive sublicense with respect to non-U.S. military sales. (2) In June 2011, the Company entered into a License Agreement with Bellco S.r.l. (“Bellco”). Under the License Agreement, as amended, the Company granted Bellco a license to manufacture, market and sell the Company’s patented mid-dilution dialysis filters (the “Products”) under its own name, label and CE mark in certain countries on an exclusive basis, and to do the same on a non-exclusive basis in certain other countries (see Note 15 – Commitments and Contingencies).
Schedule of Revenues, Net	The following tables present the Company’s revenue for the three and six months ended June 30, 2018 under the ASC 606 model as compared to revenue under the previous accounting guidance: Three Months Ended June 30, 2018 Revenue as reported Revenue under previous accounting guidance Difference Product revenue $ 1,216,000 $ 1,216,000 $ - Royalty revenue under the Sublicense Agreement with CamelBak 100,000 100,000 - Royalty revenue under the License Agreement with Bellco 31,000 31,000 - License revenue under the License Agreement with Bellco (1) - 18,000 (18,000 ) Other revenue 19,000 19,000 - Total net revenues $ 1,366,000 $ 1,384,000 $ (18,000 ) Six Months Ended June 30, 2018 Revenue as reported Revenue under previous accounting guidance Difference Product revenue $ 2,174,000 $ 2,174,000 $ - Royalty revenue under the Sublicense Agreement with CamelBak 100,000 100,000 - Royalty revenue under the License Agreement with Bellco 58,000 58,000 - License revenue under the License Agreement with Bellco (1) - 35,000 (35,000 ) Other revenue 19,000 19,000 - Total net revenues $ 2,351,000 $ 2,386,000 $ (35,000 ) (1) Under ASC 606, amounts received related to the license under the License Agreement with Bellco would have been recognized as revenue at the time that the license was transferred, which was at the time the payments were received by the Company. Under previous accounting guidance, amounts received under the License Agreement with Bellco were deferred and recognized as revenue over the term of the License Agreement.

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive: June 30, 2018 2017 Shares underlying warrants outstanding 6,642,344 7,432,342 Shares underlying options outstanding 6,644,527 5,459,015 Unvested restricted stock - 17,756

Inventory, Net (Tables)

Inventory, Net (Tables)	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory, Net	The Company’s inventory as of June 30, 2018 and December 31, 2017 was as follows: June 30, 2018 December 31, 2017 (Unaudited) (Audited) Finished goods $ 1,345,000 $ 654,000 Raw materials 74,000 51,000 Less: inventory reserve (67,000 ) (31,000 ) Total inventory, net $ 1,352,000 $ 674,000

Secured Note Payable (Tables)

Secured Note Payable (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Schedule of Future Debt Principal Maturities	As of June 30, 2018, future principal maturities are as follows: 2018 $ 101,000 2019 214,000 2020 231,000 2021 250,000 2022 271,000 2023 71,000 Total $ 1,138,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Minimum Lease Payments	As of June 30, 2018, minimum lease payments are as follows: 2018 $ 66,000 2019 136,000 2020 140,000 2021 145,000 2022 136,000
Schedule of Maturities Minimum Lease Payments Receivable	As of June 30, 2018, scheduled maturities of minimum lease payments receivable were as follows: 2018 20,000 2019 19,000 2020 22,000 61,000 Less: Current portion (31,000 ) Investment in lease, net – less current portion $ 30,000

Basis of Presentation and Liq32

Basis of Presentation and Liquidity (Details Narrative) - USD ($) $ in Thousands	Apr. 10, 2018	Jun. 30, 2018	Dec. 31, 2017
Accumulated deficit		$ 122,939	$ 121,106
Private Placement [Member]
Number of common stock shares sold, shares	6,540,669
Number of common stock shares sold, value	$ 2,943

Major Customers and Concentra33

Major Customers and Concentration of Credit Risk (Details Narrative) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018USD ($)Products	Jun. 30, 2017Products	Jun. 30, 2018USD ($)Products	Jun. 30, 2017Products	Dec. 31, 2017USD ($)Products
Allowance for doubtful accounts | $	$ 2		$ 2		$ 1
Allowance for sales returns | $
Sales Revenue Goods Net [Member]
Concentration risk, percentage	42.00%	54.00%	42.00%	56.00%
Number of major customers | Products	4	4	4	4
Accounts Receivable [Member]
Concentration risk, percentage			39.00%		29.00%
Number of major customers | Products			3		2

Major Customers and Concentra34

Major Customers and Concentration of Credit Risk - Schedule of Revenues and Receivable Major Customers (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Sales Revenue Goods Net [Member]
Concentration risk percentage	42.00%	54.00%	42.00%	56.00%
Accounts Receivable [Member]
Concentration risk percentage			39.00%		29.00%
Customer A [Member] | Sales Revenue Goods Net [Member]
Concentration risk percentage	13.00%	16.00%	14.00%	21.00%
Customer B [Member] | Sales Revenue Goods Net [Member]
Concentration risk percentage	13.00%	14.00%	13.00%	13.00%
Customer B [Member] | Accounts Receivable [Member]
Concentration risk percentage			15.00%		18.00%
Customer C [Member] | Sales Revenue Goods Net [Member]
Concentration risk percentage	11.00%	12.00%	9.00%	11.00%
Customer D [Member] | Sales Revenue Goods Net [Member]
Concentration risk percentage	5.00%	12.00%	6.00%	11.00%
Customer E [Member] | Accounts Receivable [Member]
Concentration risk percentage			12.00%		0.00%
Customer F [Member] | Accounts Receivable [Member]
Concentration risk percentage			12.00%		0.00%
Customer G [Member] | Accounts Receivable [Member]
Concentration risk percentage			0.00%		11.00%

Revenue Recognition (Details Na

Revenue Recognition (Details Narrative) $ in Thousands	Dec. 31, 2017USD ($)
License Agreement with Bellco [Member]
Deferred revenue	$ 278

Revenue Recognition - Schedule

Revenue Recognition - Schedule of License, Royal and Other Revenue (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Royalty Revenue [Member] | Sublicense Agreement [Member] | CamelBak [Member]
Revenue	[1]	$ 100	$ 25	$ 100	$ 25
Royalty Revenue [Member] | License Agreement [Member] | Bellco [Member]
Revenue		31	31	58	58
License [Member] | License Agreement [Member] | Bellco [Member]
Revenue	[2]		18		35
Other Revenue [Member]
Revenue		19		19
License, Royalty and Other Revenues [Member]
Revenue		$ 150	$ 74	$ 177	$ 118
[1]	In May 2015, the Company entered into a Sublicense Agreement with CamelBak Products, LLC ("CamelBak"). Under the Sublicense Agreement, the Company granted CamelBak an exclusive, non-transferable, worldwide (with the exception of Italy) sublicense and license, in each case solely to market, sell, distribute, import and export the Company's individual water treatment device. In exchange for the rights granted to CamelBak, CamelBak agreed, through December 31, 2022, to pay the Company a percentage of the gross profit on any sales made to a branch of the U.S. military, subject to certain exceptions, and to pay a fixed per-unit fee for any other sales made. CamelBak is also required to meet or exceed certain minimum annual fees payable to the Company, and if such fees are not met or exceeded, the Company may convert the exclusive sublicense to a non-exclusive sublicense with respect to non-U.S. military sales.
[2]	In June 2011, the Company entered into a License Agreement with Bellco S.r.l. ("Bellco"). Under the License Agreement, as amended, the Company granted Bellco a license to manufacture, market and sell the Company's patented mid-dilution dialysis filters (the "Products") under its own name, label and CE mark in certain countries on an exclusive basis, and to do the same on a non-exclusive basis in certain other countries (see Note 15 - Commitments and Contingencies).

Revenue Recognition - Schedul37

Revenue Recognition - Schedule of Revenues, Net (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue		$ 1,366	$ 859	$ 2,351	$ 1,593
Revenue Under Previous Guidance [Member]
Revenue		1,384		2,386
Difference [Member]
Revenue		(18)		(35)
Product Revenues [Member]
Revenue		1,216	785	2,174	1,475
Product Revenues [Member] | Revenue Under Previous Guidance [Member]
Revenue		1,216		2,174
Product Revenues [Member] | Difference [Member]
Revenue
Royalty Revenue [Member] | Sublicense Agreement [Member] | CamelBak [Member]
Revenue		100		100
Royalty Revenue [Member] | Sublicense Agreement [Member] | CamelBak [Member] | Revenue Under Previous Guidance [Member]
Revenue		100		100
Royalty Revenue [Member] | Sublicense Agreement [Member] | CamelBak [Member] | Difference [Member]
Revenue
Royalty Revenue [Member] | License Agreement [Member] | Bellco [Member]
Revenue		31		58
Royalty Revenue [Member] | License Agreement [Member] | Bellco [Member] | Revenue Under Previous Guidance [Member]
Revenue		31		58
Royalty Revenue [Member] | License Agreement [Member] | Bellco [Member] | Difference [Member]
Revenue
License [Member]
Revenue		150	$ 74	177	$ 118
License [Member] | License Agreement [Member] | Bellco [Member]
Revenue	[1]
License [Member] | License Agreement [Member] | Bellco [Member] | Revenue Under Previous Guidance [Member]
Revenue	[1]	18		35
License [Member] | License Agreement [Member] | Bellco [Member] | Difference [Member]
Revenue	[1]	(18)		(35)
Other Revenue [Member]
Revenue		19		19
Other Revenue [Member] | Revenue Under Previous Guidance [Member]
Revenue		19		19
Other Revenue [Member] | Difference [Member]
Revenue
[1]	Under ASC 606, amounts received related to the license under the License Agreement with Bellco would have been recognized as revenue at the time that the license was transferred, which was at the time the payments were received by the Company. Under previous accounting guidance, amounts received under the License Agreement with Bellco were deferred and recognized as revenue over the term of the License Agreement.

Stock Plans and Share-Based P38

Stock Plans and Share-Based Payments (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 124	$ 111	$ 253	$ 213
Unrecognized compensation cost	902		$ 902
Amortized over weighted average remaining requisite service period			2 years 1 month 6 days
Equity Compensation Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	1,132		$ 1,132
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	230		230
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	103	85	215	182
Unrecognized compensation cost
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	118	103	237	194
Selling, General and Administrative Expenses [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	90	85	190	182
Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	6	$ 8	16	$ 19
Stock option modification expense			12
Research and Development Expenses [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 13		$ 25

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017
Warrants [Line Items]
Warrants to purchase share of common stock	456,666	456,666
Proceeds from warrant exercises	$ 138	$ 138
Issuance of common stock, shares	456,666
Member of Management [Member]
Warrants [Line Items]
Warrants to purchase share of common stock	73,333	73,333
Proceeds from warrant exercises	$ 22

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Shares Underlying Warrants Outstanding [Member]
Excluded anti-dilutive stock options and warrants	6,642,344	7,432,342
Shares Underlying Options Outstanding [Member]
Excluded anti-dilutive stock options and warrants	6,644,527	5,459,015
Unvested Restricted Stock [Member]
Excluded anti-dilutive stock options and warrants		17,756

Recent Accounting Pronounceme41

Recent Accounting Pronouncements (Details Narrative) $ in Thousands	Dec. 31, 2017USD ($)
License Agreement [Member] | Bellco [Member]
Deferred revenue	$ 278

Inventory, Net - Schedule of In

Inventory, Net - Schedule of Inventory, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished goods	$ 1,345	$ 654
Raw materials	74	51
Less: inventory reserve	(67)	(31)
Total inventory, net	$ 1,352	$ 674

Secured Note Payable (Details N

Secured Note Payable (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Mar. 27, 2018
Repayments of notes payable	$ 72
Interest expense	$ 28	$ 64	$ 114	$ 130
Unsecured Promissory Note [Member]
Debt interest rate	11.00%		11.00%
Secured Note [Member]
Interest expense	$ 23		$ 72
Secured Promissory Note Agreement [Member] | Tech Capital, LLC [Member]
Principal amount of secured note payable					$ 1,187
Principal balance of line of credit			$ 1,138
Debt interest rate	8.00%		8.00%
Maturity date			Apr. 1, 2023
Debt instrument, maturity date, description			Principal and interest payments are due on the first day of each month commencing on May 1, 2018.
Debt issuance costs	$ 6		$ 6

Secured Notes Payable - Schedul

Secured Notes Payable - Schedule of Future Debt Principal Maturities (Details) $ in Thousands	Jun. 30, 2018USD ($)
Debt Disclosure [Abstract]
2,018	$ 101
2,019	214
2,020	231
2,021	250
2,022	271
2,023	71
Total	$ 1,138

Secured Revolving Credit Faci45

Secured Revolving Credit Facility (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Aug. 17, 2017
Interest expense	$ 28	$ 64	$ 114	$ 130
Interest expense included in accrued expenses	377		377		$ 218
Loan Agreement [Member] | Revolving Credit Facility [Member]
Revolving credit facility insurance fees	12		12
Loan Agreement [Member] | Tech Capital, LLC [Member]
Maximum secured revolving credit facility						$ 1,000
Principal balance of line of credit			$ 153		$ 711
Loan agreement, term			12 months
Line of credit interest rate			8.50%
Interest expense	3		$ 9
Loan Agreement [Member] | Tech Capital, LLC [Member] | Revolving Credit Facility [Member]
Interest expense			9
Interest expense included in accrued expenses	$ 1		$ 1
Loan Agreement [Member] | Tech Capital, LLC [Member] | Prime Rate [Member]
Line of credit interest rate			3.50%
Loan Agreement [Member] | Tech Capital, LLC [Member] | Prime Rate [Member] | Maximum [Member]
Line of credit interest rate			4.25%

Unsecured Promissory Notes an46

Unsecured Promissory Notes and Warrants (Details Narrative) - USD ($) $ in Thousands	Mar. 30, 2018	Jun. 30, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Number of warrants issued to purchase of shares of common stock			456,666		456,666
Loss on extinguishment of debt					$ (199)
Amortization of debt discount					34	54
Interest expense			$ 28	64	114	130
Lambda Investors, LLC [Member]
Due to related party							$ 300
Lambda [Member]
Interest expense related party				8	8	16
Entities Controlled by Member of Management [Member]
Due to related party							$ 30
Interest expense related party				1	1	2
Note and Warrant Agreement [Member]
Gross proceeds from unsecured promissory notes and warrants		$ 1,187
Percentage of accrued interest rate per annum		11.00%
Proceeds from warrants		$ 393
Debt issuance costs		$ 9
Amortization of debt discount				27	34	54
Interest expense				$ 33	$ 30	$ 66
Note and Warrant Agreement [Member] | Investors [Member]
Number of warrants issued to purchase of shares of common stock		2,400,000
Secured Note Agreement [Member]
Accrued interest	$ 43
Loss on extinguishment of debt	199
Secured Note Agreement [Member] | Noteholders [Member]
Interest paid	$ 195

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Apr. 10, 2018	Mar. 17, 2017	Jul. 24, 2015	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017
Class of Stock [Line Items]
Proceeds from issuance of common stock					$ 3,778,000	$ 1,179,000
Number of shares issued during period				456,666
Securities Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member]
Class of Stock [Line Items]
Stock issued during period, value, new issues			$ 10,000,000
Proceeds from issuance of common stock					$ 854,000	$ 113,000
Limited liability company description for purchase shares level			Lincoln Park, and Lincoln Park is obligated to purchase, up to $10.0 million in shares of the Company's common stock, subject to certain limitations, from time to time, over the 36-month period commencing on September 4, 2015.
Number of shares issued during period					1,900,000	300,000
Private Placement [Member]
Class of Stock [Line Items]
Number of common stock shares sold during the period	6,540,669
Private Placement [Member] | Stock Purchase Agreement [Member]
Class of Stock [Line Items]
Number of common stock shares sold during the period	6,540,669
Gross proceeds from issuance of private placement	$ 2,943,000
Shares issued price per share	$ 0.45
Proceeds of equity issuance costs net	$ 19,000
Proceeds from private placement	2,924,000
Stock issued during period, value, new issues	219,000
Proceeds from issuance of common stock	$ 98,550
Private Placement [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Number of common stock shares sold during the period		4,059,994
Gross proceeds from issuance of private placement		$ 1,218,000
Shares issued price per share		$ 0.30
Proceeds of equity issuance costs net		$ 152,000
Proceeds from private placement		$ 1,066,000
Warrants description		Each unit consisted of one share of the Company’s common stock and a five-year warrant to purchase one additional share of common stock.
Proceeds received from certain members of management and existing shareholders		$ 315,000
Number of warrants to placement agent		81,199
Exercise price per share		$ 0.33

Commitments and Contingencies48

Commitments and Contingencies (Details Narrative)	Oct. 08, 2015USD ($)	Jun. 30, 2018USD ($)Products$ / shares	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)Products$ / shares	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)ft²	Sep. 30, 2013
Commitments And Contingencies [Line Items]
Long-term intangible asset		$ 2,250,000		$ 2,250,000
Other long-term assets		1,005,000		1,005,000		$ 1,072,000
Accumulated amortization		1,245,000		1,245,000		1,178,000
Amortization of other deferred charges		33,000	$ 53,000	67,000	$ 105,000
Interest expense		2,000	2,000	12,000	10,000
Rent expense		37,000	28,000	88,000	59,000
Interest income		1,000	1,000	2,000	2,000
Investment in lease, net-current portion		31,000		31,000		20,000
Unearned interest current		2,000		2,000
Investment in lease, net-noncurrent portion		30,000		30,000		39,000
Unearned interest noncurrent		2,000		2,000
Minimum lease payments receivable		61,000		61,000
Minimum [Member]
Commitments And Contingencies [Line Items]
Minimum lease payments receivable		12,000		12,000
Accounts Payable [Member]
Commitments And Contingencies [Line Items]
Royalty expense				36,000		34,000
Cost of Goods Sold [Member]
Commitments And Contingencies [Line Items]
Royalty expense		36,000	22,000	65,000	41,000
License Agreement [Member]
Commitments And Contingencies [Line Items]
Deferred revenue						$ 278,000
Deferred revenue recognized		18,000		35,000
Operating Lease One [Member]
Commitments And Contingencies [Line Items]
Area of a land | ft²						7,700
Lease expiration date						expires in November 2022
Security deposit		$ 11,000		$ 11,000		$ 11,000
Monthly rent expense						$ 11,000
Equipment Lease Agreement [Member]
Commitments And Contingencies [Line Items]
Investment lease	$ 92,000
Unearned interest	14,000
Equipment Lease Agreement [Member] | Biocon 1, LLC [Member]
Commitments And Contingencies [Line Items]
Monthly rent expense	$ 1,800
Lease term	60 months
Bellco [Member]
Commitments And Contingencies [Line Items]
Number of units under first tier royalty receivable | Products		125,000		125,000
First tier royalty per unit | $ / shares		$ 2.10		$ 2.10
Second tier royalty per unit | $ / shares		$ 1.50		$ 1.50
Bellco [Member] | License Agreement [Member]
Commitments And Contingencies [Line Items]
Royalty income		$ 31,000	$ 31,000	$ 58,000	$ 58,000
Bellco [Member] | EUR [Member]
Commitments And Contingencies [Line Items]
First tier royalty per unit | $ / shares		$ 1.75		$ 1.75
Second tier royalty per unit | $ / shares		$ 1.25		$ 1.25
Medica Spa [Member]
Commitments And Contingencies [Line Items]
Purchase commitment				$ 1,139,000
Debt instrument, interest rate, stated percentage							12.00%
Medica Spa [Member] | December 31, 2018 [Member]
Commitments And Contingencies [Line Items]
Purchase commitment				3,000,000
Medica Spa [Member] | EUR [Member]
Commitments And Contingencies [Line Items]
Purchase commitment				949,000
Medica Spa [Member] | EUR [Member] | December 31, 2018 [Member]
Commitments And Contingencies [Line Items]
Purchase commitment				$ 2,500,000
Medica [Member] | April 23, 2014 through December 31, 2025 [Member]
Commitments And Contingencies [Line Items]
Royalty rate				3.00%

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 66
2,019	136
2,020	140
2,021	145
2,022	$ 136

Commitments and Contingencies50

Commitments and Contingencies - Schedule of Maturities Minimum Lease Payments Receivable (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 20,000
2,019	19,000
2,020	22,000
Total	61,000
Less: Current portion	(31,000)	$ (20,000)
Investment in lease, noncurrent	$ 30,000